ProKidney (PROK) Projected to Post Quarterly Earnings on Tuesday

ProKidney (NASDAQ:PROK) will likely be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.0440 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

ProKidney (NASDAQ:PROK) last posted its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. The business had revenue of $0.22 million during the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Stock Performance

PROK stock opened at $2.80 on Tuesday. The firm has a fifty day moving average price of $2.76 and a 200 day moving average price of $2.03. The firm has a market cap of $823.98 million, a PE ratio of -4.92 and a beta of 1.75. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $7.13.

Analyst Upgrades and Downgrades

Several research firms have commented on PROK. UBS Group lifted their price objective on shares of ProKidney from $4.00 to $8.00 and gave the stock a “buy” rating in a research note on Tuesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research note on Wednesday, October 8th. Zacks Research lowered shares of ProKidney from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Guggenheim reaffirmed a “buy” rating and set a $7.00 price objective (up from $6.00) on shares of ProKidney in a research note on Monday, July 14th. Finally, Citigroup reaffirmed a “buy” rating and set a $9.00 price objective (up from $6.00) on shares of ProKidney in a research note on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.25.

Hedge Funds Weigh In On ProKidney

A number of large investors have recently added to or reduced their stakes in PROK. AQR Capital Management LLC boosted its position in ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after buying an additional 27,098 shares during the last quarter. Marshall Wace LLP purchased a new stake in ProKidney in the second quarter valued at approximately $274,000. Jane Street Group LLC purchased a new stake in ProKidney in the second quarter valued at approximately $350,000. Bank of America Corp DE boosted its position in ProKidney by 12.4% in the second quarter. Bank of America Corp DE now owns 846,154 shares of the company’s stock valued at $501,000 after buying an additional 93,322 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in ProKidney by 3,024.9% in the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after buying an additional 1,615,243 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.